Skip to content
value.today
Cytek BioSciences, Inc. logo

Cytek BioSciences, Inc.

Formerly Cytoville, Inc.

Total raised
$120 M
1 round on record
Latest round
$120 M
Oct 2020
First round on record
Oct 2020
Today
Went public
See the company page

Cytek BioSciences, Inc. is listed today as Cytek Biosciences, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cytek BioSciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2020$120 MNo. 1$50 to $250 million

Cytek BioSciences, Inc.: Raise no. 1, Oct 2020

Investors in this round

14 investors had bought by the notice of Nov 10, 2020: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Cytek BioSciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$120 M of $120 M offered
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ming Yan · Executive Officer, Director
  • Wenbin Jiang · Executive Officer, Director
  • Allen Poirson · Director
  • Andrew Levin · Director
  • Feng Deng · Director
  • Jack Ball · Director
  • Jiecheng Zhang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Wenbin Jiang, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 10, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Cytek Biosciences, Inc., its revenue in fiscal 2025 came from these business segments: Reportable $201.49 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Cytek BioSciences, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2020).

    SEC Form D · Nov 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2020

Products and services#

No products or services of Cytek BioSciences, Inc. are on record.

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in Cytek BioSciences, Inc.
InvestorKindAmountRoundRoleSource
RA Capital Healthcare Fund LPFund or asset managernot statednot statedHeld Series D preferred stock, director (Form 3, 2021)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, director (Form 3, 2021)SEC Form 3
RA Capital Nexus Fund II, L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, director (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 14 investors.

Largest shareholders today

Institutions holding Cytek Biosciences, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cytek BioSciences, Inc.
NameRoleNamed in
Ming YanExecutive officerNov 2020
Wenbin JiangExecutive officerNov 2020
Allen PoirsonDirectorNov 2020
Andrew LevinDirectorNov 2020
Feng DengDirectorNov 2020
Jack BallDirectorNov 2020
Jiecheng ZhangDirectorNov 2020
Ming YanDirectorNov 2020
Wenbin JiangDirectorNov 2020

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.